Cargando…

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

[Image: see text] The central nervous system (CNS) is the major area that is affected by aging. Alzheimer’s disease (AD), Parkinson’s disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment. Achievement of appropriate blood–brain barrier (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghose, Arup K., Herbertz, Torsten, Hudkins, Robert L., Dorsey, Bruce D., Mallamo, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260741/
https://www.ncbi.nlm.nih.gov/pubmed/22267984
http://dx.doi.org/10.1021/cn200100h
_version_ 1782221518300774400
author Ghose, Arup K.
Herbertz, Torsten
Hudkins, Robert L.
Dorsey, Bruce D.
Mallamo, John P.
author_facet Ghose, Arup K.
Herbertz, Torsten
Hudkins, Robert L.
Dorsey, Bruce D.
Mallamo, John P.
author_sort Ghose, Arup K.
collection PubMed
description [Image: see text] The central nervous system (CNS) is the major area that is affected by aging. Alzheimer’s disease (AD), Parkinson’s disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment. Achievement of appropriate blood–brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process. On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochemical and structural differences between CNS and non-CNS drugs may assist both research areas. Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena. Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compounds, we analyzed the physicochemical property and the chemical structural profiles of 317 CNS and 626 non-CNS oral drugs. The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process. A list of substructural units that may be useful for CNS drug design was also provided here. A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs. The combined analysis provided the following guidelines for designing high-quality CNS drugs: (i) topological molecular polar surface area of <76 Å(2) (25–60 Å(2)), (ii) at least one (one or two, including one aliphatic amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) volume of 740–970 Å(3), (vi) solvent accessible surface area of 460–580 Å(2), and (vii) positive QikProp parameter CNS. The ranges within parentheses may be used during lead optimization. One violation to this proposed profile may be acceptable. The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.
format Online
Article
Text
id pubmed-3260741
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-32607412012-01-19 Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery Ghose, Arup K. Herbertz, Torsten Hudkins, Robert L. Dorsey, Bruce D. Mallamo, John P. ACS Chem Neurosci [Image: see text] The central nervous system (CNS) is the major area that is affected by aging. Alzheimer’s disease (AD), Parkinson’s disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment. Achievement of appropriate blood–brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process. On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochemical and structural differences between CNS and non-CNS drugs may assist both research areas. Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena. Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compounds, we analyzed the physicochemical property and the chemical structural profiles of 317 CNS and 626 non-CNS oral drugs. The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process. A list of substructural units that may be useful for CNS drug design was also provided here. A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs. The combined analysis provided the following guidelines for designing high-quality CNS drugs: (i) topological molecular polar surface area of <76 Å(2) (25–60 Å(2)), (ii) at least one (one or two, including one aliphatic amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) volume of 740–970 Å(3), (vi) solvent accessible surface area of 460–580 Å(2), and (vii) positive QikProp parameter CNS. The ranges within parentheses may be used during lead optimization. One violation to this proposed profile may be acceptable. The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented. American Chemical Society 2011-11-02 /pmc/articles/PMC3260741/ /pubmed/22267984 http://dx.doi.org/10.1021/cn200100h Text en Copyright © 2011 American Chemical Society http://pubs.acs.org This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org.
spellingShingle Ghose, Arup K.
Herbertz, Torsten
Hudkins, Robert L.
Dorsey, Bruce D.
Mallamo, John P.
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
title Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
title_full Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
title_fullStr Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
title_full_unstemmed Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
title_short Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
title_sort knowledge-based, central nervous system (cns) lead selection and lead optimization for cns drug discovery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260741/
https://www.ncbi.nlm.nih.gov/pubmed/22267984
http://dx.doi.org/10.1021/cn200100h
work_keys_str_mv AT ghosearupk knowledgebasedcentralnervoussystemcnsleadselectionandleadoptimizationforcnsdrugdiscovery
AT herbertztorsten knowledgebasedcentralnervoussystemcnsleadselectionandleadoptimizationforcnsdrugdiscovery
AT hudkinsrobertl knowledgebasedcentralnervoussystemcnsleadselectionandleadoptimizationforcnsdrugdiscovery
AT dorseybruced knowledgebasedcentralnervoussystemcnsleadselectionandleadoptimizationforcnsdrugdiscovery
AT mallamojohnp knowledgebasedcentralnervoussystemcnsleadselectionandleadoptimizationforcnsdrugdiscovery